Navigation Links
Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First IND
Date:3/11/2011

BURLINGAME, Calif., March 11, 2011 /PRNewswire/ -- Apexigen, Inc., an emerging biopharmaceutical company focusing on the development of monoclonal antibody therapeutics, announced today that its partner, Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) of China to evaluate APX003 (also known as BD0801) as a potential cancer therapy.  APX003 is a humanized monoclonal antibody directed against VEGF, and is intended for the treatment of multiple malignancies.  Upon review and approval of the IND application by the SFDA, Simcere plans to initiate Phase 1 safety and tolerability studies in cancer patients.

Simcere will develop and commercialize APX003 in China under a license agreement with Apexigen.  In 2008, Simcere acquired rights to APX003 from Epitomics, Inc.  Then in July of 2010, Epitomics created Apexigen as an independent therapeutic antibody company, licensed to Apexigen exclusive rights to the use of its antibody technologies for the development and commercialization of antibody therapeutics, and assigned to Apexigen the license and collaboration agreement with Simcere.  Apexigen and Simcere collaborated on the IND enabling studies and on the completion of the IND for APX003.

The initiation of this Phase 1 clinical study will mark a significant milestone for Apexigen.  APX003 will be the first humanized antibody generated through the use of its technology to be administered to humans.  

"This is an exciting time for Apexigen.  We are eager to see the first of our antibodies demonstrate safety, tolerability and efficacy in man as a first step toward the development of best-in-class therapeutics," said Dr. Xiaodong Yang, President & CEO of Apexigen.  "The collaboration with
'/>"/>

SOURCE Apexigen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 A ... the NCATS rare-diseases portfolio " in Science ... new financing technique to reduce the risk associated ... and potentially unlock new levels of funding for ... product of a unique collaboration between scientists at ...
(Date:2/27/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY) is to present important ... patients with metastatic renal cancer at the ASCO Genitourinary ... The data will be presented by Dr. Sumanta ... Center in California in his ... Ferritin and IL-8 as two baseline biomarkers that correlate ...
(Date:2/27/2015)...  Steep Hill, the industry leader in cannabis testing ... open a full service medical cannabis quality assurance laboratory ... advanced scientific tools and methodology to the state, for ... currently the only laboratory licensed by the New Mexico ... in order to meet the recently adopted regulatory requirements ...
(Date:2/26/2015)... , Feb. 26, 2015  23andMe, the leading ... Kate Black as Privacy Officer and Corporate Counsel. ... state privacy laws as well as health care regulations. ... she will be responsible for reviewing, updating and enhancing ... the U.S. and abroad. She joined the company January ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 223andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2
... Oct. 24 Cardiogenesis,Corporation (OTC: CGCP), announced that ... ended September 30, 2007 prior to market open ... that President Richard,P. Lanigan and Senior Vice President ... an investor conference call that day at 12:00 ...
... - Continued Strong Organic Growth, With Revenue Up 8.5% Like-for-Like Essilor International, the world ... Consolidated revenue for the first nine months, EUR millions ... % change Like-for-like ... months) ...
... in German . , Hydrogen fuel cells will ... far suffered from being insufficiently competitive. At the University of ... now developed a new class of electrocatalyst that could help ... of the catalyst consists of nanoparticles with a platinum-rich shell ...
Cached Biology Technology:Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th 2Essilor's 2007 Third-Quarter Report 2Essilor's 2007 Third-Quarter Report 3Essilor's 2007 Third-Quarter Report 4Platinum-rich shell, platinum-poor core 2
(Date:2/24/2015)... Feb. 24, 2015 Research and Markets ... of the "Global 2D Gesture Recognition Market ... The analysts forecast the Global 2D Gesture ... 32.12% over the period 2014-2019 The ... sectors is one of the major trends in ...
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... BOSTON The eon-spanning clock of evolution the ... traits belies a constant ferment in the chambers and ... subtle ripple effects throughout an organism. In a study ... at Dana-Farber Cancer Institute,s Center for Cancer Systems Biology and ...
... Physicians at University Hospitals (UH) Rainbow Babies and Children,s ... the national research consortium AsthmaNet. UH Rainbow, one ... has partnered with University of Pittsburgh Medical Center (through ... on these studies and future asthma clinical research studies ...
... most influential researchers, whose pioneering work in chemical analysis ... top chemists, is set to receive two major, highly ... O. Lawton Professor of Chemistry and Biochemistry at Florida ... at the National High Magnetic Field Laboratory, will receive ...
Cached Biology News:1st large-scale map of a plant's protein network addresses evolution, disease process 21st large-scale map of a plant's protein network addresses evolution, disease process 31st large-scale map of a plant's protein network addresses evolution, disease process 4UH Rainbow Babies and Children's Hospital opens asthma studies 2UH Rainbow Babies and Children's Hospital opens asthma studies 3Acclaimed chemistry professor wins 2 major awards 2Acclaimed chemistry professor wins 2 major awards 3
...
... E F L P E P Q H ... L E(19) PA1-072 detects munc-18 interacting protein 3 ... in Western blot procedures. By Western blot, ... Mint3 from AtT20 cell extract.,PA1-072 immunizing peptide corresponds ...
... (AR) Competitor Assay Kits provide a sensitive ... potential AR ligands using fluorescence polarization (FP). ... domain protein tagged with His and GST ... androgen ligand (Fluormone AL Green in the ...
... for complex protein processing and production challenges. We ... you develop a solution to your problem and then ... do additional work/scale-up processes ... transfer all methodology to your own lab , ...
Biology Products: